OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

296 reduced price

just shows what a nonsense this sp movement this week has been. its all oil and mining at the moment but remember:

The Time could really be good now for OXB. The most attractive investment opportunities often arise in sectors which have done little to set investors' pulses racing over recent years. Investors' attitudes to them can become dismissive, so they spend little time examining them closely. Spotting when things are about to turn around is the key. OXB has the potential of several Blockbuster drugs and the years of research and trials are starting to pay off with some very exciting results (see co. website and news releases for more info)

On top of that is the cyclical nature of the Biotech sector and from the graphs of OXB and the sector, the chances of a Biotech sector rally are high. According to Framlington this area appears to be priced about 35% below its historical average, hopefully giving plenty of scope for prices to increase. In addition, as the industry has begun to mature there is a large pipeline of new products coming through.

And on top of that, there are big noises from large predators who are eagre to get their hands on the Bio Blockbusters of the future:

From Times Online 1/8/05: http://business.timesonline.co.uk/section/0,,9068,00.html

JAPANS biggest pharmaceutical group has amassed a 1.5 trillion yen (8 billion) war chest and is planning an acquisition spree as it vies for global competitiveness with rivals such as GlaxoSmithKline and Pfizer.
Although a drugs titan in Japan, Takeda ranks only 14th in the world a position that the groups president is eager to improve. In an exclusive interview with The Times, Yasuchika Hasegawa described a desire to put his group on the global map by using its cash to create a pipeline of blockbuster drugs.

With all these factors mounting, the outlook for OXB is looking very interesting.

Indeed they are - but hopefully the sp will go down to the 28/29p range so that I can buy in, before rebounding on further good news.

More licencing agreements, before long they'll be cash flow positive. A rights is not needed and Oxb is gaining international recognition. A doctor friend of mine recently bought into these, they get all the trade articles which must have impressed her, once again we are at bargain price and any further fall will be sure to trigger takeover talk again.

An anlaysis of the trdes today suggests institutional support at these levels, any further news should propell it back above 40, 45

another large buy 500k at 37

Has anybody read anything lately about OXB ? - something has put the spooks up investors or mms.

It's just shorters IMHO.
UC.

I've just read this item in tonight's Stock Market report from UK-Analyst. Their view is that today's slide in the share price is unwarranted!

Oxford BioMedica, the gene therapy company, saw its shares ease 2.5p to 27.5p as investors bailed out on news of an imminent fundraising. The slide would appear to have been unwarranted, with the company announcing good progress with its registration plans and details of a Phase III trial with its lead cancer immunotherapy, TroVax, in renal cell carcinoma. Meanwhile, it was news of a proposed 20-30 million dollar placing and open offer that concerned investors, who speculated over what level of discount might or might not be applied.

Not sure why the sp reacted so badly to speculation of fundraising. The fundamentals haven't changed and they still have plenty of cash in the bank. They want to fasttrack the trials without delay of signing up a partner (although thats still a possibility) AK is obviously very confident and by going it alone will mean all the more benefit to shareholders, whilst control is very much with OXB. Personally I think going it alone would be the better option and 20-30m worth of shares bought by institutions at a discount is small price to pay, may even be at a premium!! No bad news here, in fact OXB now even more vulnerable to a bid which would be a great shame. Should soon return to 40p and on to 50+ once this glitch has been forgotten.

Whats more, the shorters of this stock will have to buy back soon, that has only just begun, a lot of automatic trades coming in now. There isn't going to be much selling at this price, Placing or no Placing.

Buys outnunbering sells but mms reluctant to raise the price, analysing the trades over the past week, mms must have lost a lot, they were buying in down to current levels and now buyers are mopping them back at lower prices, it shouldn't be long before a rally, some news would help re the placing at 33p which i heard was the minimum being considered, or someone building a stake which is most likely at these prices.

somethings been leaked - see over on Advfn re govt funding, could be interesting, no need for the placing?

Up 14% since 2.00pm today, anyone know why?

Now 19% wow!

Placing must have closed and as I said it's well oversubscribed and not at a discount. Shorters have to close their positions so this will bounce quicker than they can get back in.

some say the 30p level for the placing is fact, one bloke on iii forecast a big rise this pm, when the price was minus, excellent.

Share price fell from 45p to 25p much like VOG did! Placing completed last month as happened with VOG. Keep a watchful eye on OXB.News is expected soon and buyers returned today after retrace.Needs to hold support at 30p and breakout occurs above 32.5p. Personally expecting shorter and swifter rise back to 45p target price.Short term moves suggest 34p-36p.Plenty more news expected in 2006.Chart has resumed rising trend and high volumes by close today.

1.Link to most recent charts by Fingers xxxd
http://www.advfn.com/cmn/fbb/thread.php3?id=5456944&from=3940

2.Updated company presentation:


http://www.oxfordbiomedica.co.uk/pdfs/presentation.pdf

3.http://www.advfn.com/cmn/fbb/thread.php3?id=10614907
melfaraj - 8 Jan'06 - 13:50 - 286 of 288


oxb,

has risen from a bot of 26p and currently stands at 31.5.
looking very good. note rising volume. long term ma should be responding to the continued rises soon and begin to head north.
lovely round bottom too!

4.http://www.advfn.com/cmn/fbb/thread.php3?id=7999692

151 issued or granted patents (portfolio of over 80 patent families)
Comprehensive protection at both technology and product levels
Freedom to operate for all product candidates
Broad ownership of key technologies including:
5T4 tumour antigen platform (TroVax) to 2019
P450 gene prodrug technology (MetXia) to 2015
LentiVector gene delivery system to 2021

Stong moves on low volumes.OXB strong buy on 20 ma and 50 ma cross, longer term ma coming together and becomes buy on confirmation of chart breakout.Becomes a self fulfilling prophesy Without news short term target suggester 40p-45p and more immediate over several trading days 34p-36p.Expect traders will top slice banking profits 35p-36p.Currently 32.25p-32.75p and may be lucky if offer dips back 32.5p.Time to be holding 2006/2007.